MARKET

TARS

TARS

Tarsus Pharmaceuticals, Inc.
NASDAQ
64.62
+2.63
+4.24%
After Hours: 64.62 0 0.00% 16:10 02/06 EST
OPEN
62.55
PREV CLOSE
61.99
HIGH
64.79
LOW
62.37
VOLUME
799.58K
TURNOVER
--
52 WEEK HIGH
85.25
52 WEEK LOW
38.51
MARKET CAP
2.74B
P/E (TTM)
-32.0950
1D
5D
1M
3M
1Y
5Y
1D
Shareholders Should Be Pleased With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Price
Simply Wall St · 1d ago
Tarsus Pharmaceuticals price target raised to $68 from $51 at Goldman Sachs
TipRanks · 2d ago
Allspring Emerging Growth Fund Q4 2025 Performance Review
Seeking Alpha · 2d ago
Weekly Report: what happened at TARS last week (0126-0130)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: Erasca (ERAS) and Tarsus Pharmaceuticals (TARS)
TipRanks · 01/26 11:30
Weekly Report: what happened at TARS last week (0119-0123)?
Weekly Report · 01/26 10:02
Weekly Report: what happened at TARS last week (0112-0116)?
Weekly Report · 01/19 10:07
Relative Strength Alert For Tarsus Pharmaceuticals
NASDAQ · 01/15 17:04
More
About TARS
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

Webull offers Tarsus Pharmaceuticals Inc stock information, including NASDAQ: TARS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARS stock methods without spending real money on the virtual paper trading platform.